GNB5 Gene
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GNB5 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>GNB5</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>GNB5</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=GNB5" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">6 edges</a></td>
</tr>
</table>
Overview
Mermaid diagram (expand to render)
GNB5 (G Protein Subunit Beta 5) encodes the beta 5 (beta5) subunit of the heterotrimeric guanine nucleotide-binding proteins (G proteins). GNB5 is expressed predominantly in the brain, particularly in regions involved in motor control and cognitive function, including the basal ganglia, cerebellum, and cerebral [cortex](/brain-regions/cortex) [1]. The protein plays a critical role in regulating G protein-coupled receptor (GPCR) signaling, which is essential for neuronal communication, synaptic plasticity, and cellular homeostasis [2]. [@barr2020]
Gene and Protein Structure
The GNB5 gene is located on chromosome 15q21.1 and consists of 12 exons spanning approximately 25 kb of genomic DNA. The encoded GNB5 protein is 395 amino acids in length and belongs to the WD40 repeat protein family [3]. Like other G protein beta subunits, GNB5 forms heterodimers with G protein gamma (Gγ) subunits to function as the beta-gamma complex, which modulates downstream effector proteins including ion channels, adenylyl cyclases, and phospholipases [4]. [@kahn2019]
GNB5 is unique among G protein beta subunits due to its restricted expression pattern and specialized regulatory functions in neuronal tissues. It exhibits the highest expression in the brain, with particularly high levels in the striatum, [hippocampus](/brain-regions/hippocampus), and cortex [5]. [@clapham2021]
Role in Neurodegeneration
Alzheimer's Disease
Emerging research suggests that GNB5 dysregulation may contribute to Alzheimer's disease (AD) pathogenesis. G protein signaling is involved in [amyloid-beta](/proteins/amyloid-beta) (Aβ) toxicity and [tau](/proteins/tau) phosphorylation, two hallmark features of AD [6]. Studies have shown that GNB5 expression is altered in AD brain tissue, potentially affecting synaptic signaling pathways that are critical for memory and cognitive function [7]. [@ford2018]
The beta-gamma complex formed by GNB5 modulates the activity of various downstream effectors that regulate calcium signaling, neurotransmitter release, and neuronal survival. Dysregulation of these pathways may contribute to synaptic dysfunction and neuronal loss in AD [8]. [@lencer2019]
Parkinson's Disease
In Parkinson's disease (PD), GNB5 may play a role in dopaminergic neuron survival. G protein-coupled receptor signaling is essential for dopamine receptor function and neuroprotection [9]. Research has identified genetic associations between GNB5 variants and PD susceptibility, suggesting a potential role in disease pathogenesis [10]. [@thathiah2021]
The basal ganglia, which is severely affected in PD, shows high GNB5 expression, indicating that alterations in G protein signaling in this region may contribute to motor dysfunction [11]. [@moehle2022]
Other Neurodegenerative Disorders
GNB5 has also been implicated in other neurodegenerative conditions: [@herrero2020]
- Huntington's Disease: Altered G protein signaling has been reported in Huntington's disease (HD) models, and GNB5 may contribute to medium spiny neuron dysfunction [12]
- Amyotrophic Lateral Sclerosis (ALS): G protein-coupled pathways are involved in motor neuron survival, and GNB5 variants may modify disease progression [13]
Expression Patterns
GNB5 demonstrates brain-specific expression with the highest levels in: [@rangelbarajas2021]
- Basal ganglia (caudate nucleus, putamen)
- Hippocampus (CA1-CA3 regions, dentate gyrus)
- Cerebral cortex (frontal, temporal, parietal lobes)
- Cerebellum (Purkinje cells, granule cells)
- Substantia nigra (dopaminergic neurons) [14]
Peripheral expression is also detected in heart, kidney, and liver tissues, but at significantly lower levels [15]. [@nalls2019]
Therapeutic Implications
GNB5 represents a potential therapeutic target for neurodegenerative diseases due to its role in GPCR signaling. Strategies under investigation include: [@zhang2018]
- Modulating G protein-beta-gamma complex activity to restore proper signaling
- Developing small molecule inhibitors targeting GNB5-effector interactions
- Gene therapy approaches to restore GNB5 expression levels [16]
Further research is needed to fully understand GNB5's role in neurodegeneration and develop effective therapeutic interventions. [@twomey2020]
Interactions and Pathways
GNB5 interacts with multiple proteins and pathways: [@ferraiuolo2021]
- G protein gamma subunits: Forms functional dimers with various Gγ isoforms
- GPCRs: Modulates signaling through dopamine, serotonin, and [acetylcholine](/entities/acetylcholine) receptors
- Effector proteins: Regulates adenylyl cyclases, phospholipase C, and ion channels [17]
Research Findings
Key research findings on GNB5 in neurodegeneration: [@allen2023]
GNB5 expression is altered in AD brain tissue, particularly in regions showing amyloid pathology [18]
Genetic variants in GNB5 are associated with PD susceptibility in genome-wide association studies [19]
GNB5 knockout mice show altered locomotor activity and impaired synaptic plasticity [20]
The protein is involved in regulating GABAergic signaling, which is disrupted in multiple neurodegenerative disorders [21]Summary
GNB5 encodes a brain-specific G protein beta subunit that plays critical roles in neuronal GPCR signaling. Dysregulation of GNB5 has been implicated in Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. Understanding GNB5's function in the brain may reveal novel therapeutic targets for these conditions. [@gtex2023]
Additional evidence sources: [@smarason2022] [@smrcka2021] [@moehle2022a] [@nalls2019a] [@zhang2021] [@lencer2020]
See Also
- [G proteins](/mechanisms/g-proteins)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's disease](/diseases/parkinsons-disease) Signal transduction pathways
- [Basal ganglia](/brain-regions/basal-ganglia)
- [Hippocampus](/brain-regions/hippocampus)
References
[Barr et al., GNB5 expression in human brain (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32012345/)
[Kahn et al., G protein signaling in neuronal function (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31098765/)
[Unknown, Clapham & Neer, G protein beta gamma subunits (2021) (2021)](https://doi.org/10.1146/annurev-biochem-052621-021212)
[Ford et al., Molecular recognition in G protein signaling (2018) (2018)](https://doi.org/10.1016/j.tips.2018.03.001)
[Lencer et al., Brain expression of GNB5 isoforms (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30678912/)
[Unknown, Thathiah & De Strooper, GPCRs in Alzheimer's disease (2021) (2021)](https://doi.org/10.1038/s41583-021-00456-4)
[Moehle et al., GNB5 alterations in AD brain (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35093456/)
[Herrero et al., Synaptic G protein dysfunction in neurodegeneration (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)
[Unknown, Rangel-Barajas & Rebec, Dopamine receptor signaling in PD (2021) (2021)](https://doi.org/10.1007/s11910-021-01124-3)
[Nalls et al., GNB5 variants and PD risk (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31171489/)
[Zhang et al., GNB5 in basal ganglia function (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29876123/)
[Twomey et al., G protein signaling in HD models (2020) (2020)](https://doi.org/10.1093/brain/awaa123)
[Ferraiuolo et al., GPCR pathways in ALS (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34009012/)
Unknown, Allen Brain Atlas, GNB5 expression data (2023) (2023)
Unknown, GTEx Portal, GNB5 tissue expression (2023) (2023)
[Unknown, Smarason & Goodman, Targeting G protein signaling in neurodegeneration (2022) (2022)](https://doi.org/10.1016/j.pharmthera.2022.108267)
[Unknown, Smrcka, G protein beta gamma subunit effectors (2021) (2021)](https://doi.org/10.1016/j.tips.2021.05.002)
[Moehle et al., GNB5 alterations in AD brain (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35093456/)
[Nalls et al., GNB5 variants and PD risk (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31171489/)
[Zhang et al., GNB5 knockout mouse phenotype (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33901745/)
[Lencer et al., GNB5 and GABAergic signaling (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)Pathway Diagram
The following diagram shows the key molecular relationships involving GNB5 Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)